BiomX Inc.

BiomX Inc. (NYSE American: PHGE) is a clinical-stage biopharmaceutical company focused on developing phage-based therapies targeting chronic diseases caused by bacteria, with programs in areas including inflammatory bowel disease and skin conditions. The company went public in October 2019 through a merger with Chardan Healthcare Acquisitions Corp., a blank-check company sponsored by Chardan Capital Markets, a healthcare-focused investment bank. BiomX filed an 8-K with the SEC on August 28, 2026, under accession number 0001213900-26-095146, reflecting ongoing public-company reporting obligations. The company operates in the biotechnology and life sciences sector. Visit SpacDesk and sign up for full data, filings, and deal analytics on BiomX and hundreds of other SPAC-linked companies.